🇪🇺 Brentuximab Vedotin - induction in European Union

EMA authorised Brentuximab Vedotin - induction on 25 October 2012

Marketing authorisation

EMA — authorised 25 October 2012

  • Application: EMEA/H/C/002455
  • Marketing authorisation holder: Takeda Pharma A/S
  • Local brand name: Adcetris
  • Indication: Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated
  • Status: approved

Read official source →

Other Oncology approved in European Union

Frequently asked questions

Is Brentuximab Vedotin - induction approved in European Union?

Yes. EMA authorised it on 25 October 2012.

Who is the marketing authorisation holder for Brentuximab Vedotin - induction in European Union?

Takeda Pharma A/S holds the EU marketing authorisation.